Foundayo cut sleep apnea events by 44% without PAP. Can Lilly turn an obesity pill into its next OSA franchise?
Foundayo cut sleep apnea events by up to 44% in Phase 3 ATTAIN-OSA, giving Eli Lilly another potential obesity-linked OSA treatment.
Pharma & Biotech
Features & Analysis
Can branded GLP-1 medicines replace compounded weight-loss drugs in Hims & Hers growth strategy?
Lilly is bringing Zepbound and Foundayo to Hims & Hers, turning a former GLP-1 disruptor into a branded obesity-drug distribution channel.
Pharma & Biotech
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Eli Lilly and Hims & Hers expand access to Zepbound and Foundayo from $149 monthly. Discover the impact on obesity medicine distribution.
Features & Analysis
Why small-molecule GLP-1 pills could matter even if injectable obesity drugs remain more powerful
Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
Pharma & Biotech
Evidation GLP-1 study reveals major growth runway but exposes widening access gaps
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Pharma & Biotech
Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Pharma & Biotech
Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.
Pharma & Biotech
Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.
Features & Analysis
Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can
Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound)
Pharma & Biotech
Eli Lilly’s $6bn API plant in Alabama signals new era in U.S. peptide drug manufacturing
Eli Lilly’s $6B Alabama facility will manufacture orforglipron and peptide APIs. Explore how this reshoring move could transform U.S. drug manufacturing.